TRANSCRIPT 🔗
WEBVTT
00:00:00.560 --> 00:00:02.879
We all know someone who's battled cancer.
00:00:03.040 --> 00:00:07.360
It's a foe that doctors and researchers have been dealing with for many years.
00:00:07.599 --> 00:00:15.039
But how has cancer research and treatment evolved to make fighting cancer more customized and personalized for patients?
00:00:15.279 --> 00:00:19.679
Find out today on the University of Saskatchewan Signature Series Podcast.
00:00:26.079 --> 00:00:36.960
Welcome to today's episode of the USASK Signature Series Podcast, where we explore some of the incredible work happening in research, scholarly, and artistic works on the university campus.
00:00:37.200 --> 00:00:45.439
I am your host, Matt Olson, and with me today, I cannot think of a better guest to talk about cancer research and treatment than Franco Vizekumar.
00:00:45.600 --> 00:00:55.039
Franco is a professor in the Department of Oncology with the University of Saskatchewan's College of Medicine and is a senior research scientist with the Saskatchewan Cancer Agency.
00:00:55.200 --> 00:01:03.920
His lab group has been exploring new avenues for treating cancer with a special focus on genomics-based research, which we will absolutely be getting into today.
00:01:04.000 --> 00:01:05.760
But Franco, welcome to the podcast.
00:01:05.920 --> 00:01:06.719
It's great to have you.
00:01:07.040 --> 00:01:07.760
Thank you, Matt.
00:01:07.840 --> 00:01:08.719
Thank you for having me.
00:01:09.040 --> 00:01:12.079
And it is one of our new podcasts, doing it all on video.
00:01:12.319 --> 00:01:15.200
So we've got cameras all around us and microphones in front of us.
00:01:15.280 --> 00:01:20.799
And we are so excited to talk about some of this incredible cancer research that you've been doing.
00:01:21.040 --> 00:01:30.319
But before we get too deep into that, can you start by telling us about your position at the university and with the SCA and the kind of research you're doing?
00:01:30.719 --> 00:01:37.760
As you correctly pointed out, um I'm a professor in the Department of Oncology within the College of Medicine at the University of Saskatchewan.
00:01:37.920 --> 00:01:39.920
And I'm also a senior scientist.
00:01:40.000 --> 00:01:43.439
That's my primary affiliation with the Saskatchewan Cancer Agency.
00:01:43.680 --> 00:01:48.879
And my lab focuses heavily on cancer research, and that's what we do.
00:01:49.280 --> 00:01:50.000
Absolutely.
00:01:50.239 --> 00:02:02.640
And now we're going to start really broad today before getting into the nitty-gritty, because the work that you're doing is very, very specific and very customized and very down to that micro, sub-micro kind of level.
00:02:02.799 --> 00:02:05.680
So let's start really broad today, Franco.
00:02:06.079 --> 00:02:10.719
What is cancer and why is it so hard for doctors to treat?
00:02:11.039 --> 00:02:14.400
Well, cancer is not a single disease, right?
00:02:14.560 --> 00:02:20.080
Like it's actually a group of, like,
Load full transcript
I can say even almost uh 100 to 200 different diseases.
00:02:20.240 --> 00:02:20.560
Okay.
00:02:20.960 --> 00:02:26.319
And and you know, we even talk about like pancreatic cancer or prostate cancer.
00:02:26.560 --> 00:02:31.280
And within those cancers itself, there are multiple subtypes of different cancers.
00:02:31.360 --> 00:02:35.599
And so as we are exploring, there are so many different types of cancers.
00:02:36.400 --> 00:02:52.800
And why is it really so difficult to treat is simply because of uh a factor called heterogeneity, which is basically a single tumor is not exactly like all similar group of cell population.
00:02:53.120 --> 00:02:54.479
They are entirely different.
00:02:54.719 --> 00:02:58.560
So that's why we often find ourselves struggling in the clinic.
00:02:58.639 --> 00:03:08.080
You might actually find two patients exactly very similar clinical presentations, but at the molecular level, their cancer is entirely different.
00:03:08.240 --> 00:03:12.000
And so one may respond to a therapy, the other one may not.
00:03:12.240 --> 00:03:22.240
And so the goal of our cancer research is to actually find why and how we can actually make it more personalized so everybody can respond to specific therapies.
00:03:22.560 --> 00:03:26.479
So despite like it could be two people with the same, you mentioned pancreatic cancer.
00:03:26.560 --> 00:03:26.639
Yeah.
00:03:26.800 --> 00:03:38.319
You could have two patients with pancreatic cancer, but even in that case, similar like similar health, similar backgrounds, similar uh um histories in that way, and those cancers could still look extremely different.
00:03:38.639 --> 00:03:38.960
Exactly.
00:03:39.120 --> 00:03:48.560
So the the funny thing is like somewhere in the early 1800s, a French scientist actually uh classified cancer based on body parts, right?
00:03:48.639 --> 00:03:50.000
Like from where it occurs.
00:03:50.319 --> 00:03:52.560
So if it happens in breast, it is breast cancer.
00:03:52.639 --> 00:03:55.680
If it happens in in prostate, it's prostate cancer.
00:03:55.840 --> 00:04:00.319
And it has been one of the ways that we've been looking at cancer for a long time.
00:04:00.879 --> 00:04:16.879
But with the advent of uh DNA sequencing of all of these tumors, what we've actually found is there can be a pancreatic cancer patient and there is a prostate cancer patient, they both can have very similar genetic alterations.
00:04:17.120 --> 00:04:27.680
And so I I always jokingly say, you know, we have to move towards rather than having a breast cancer clinic, we should have a P10 clinic or a Keras clinic.
00:04:27.759 --> 00:04:30.800
So these are the genetic mutations that happens within these cancers.
00:04:30.959 --> 00:04:31.199
Right.
00:04:31.360 --> 00:04:47.680
And so if we can actually group patients based on their molecular signatures of the mutation that is present within those tumor cells, and then bring that treatment into a modality, probably we might actually have a better chance.
00:04:48.000 --> 00:04:48.480
Right.
00:04:48.879 --> 00:04:51.759
Now you talked about history and historically.
00:04:51.839 --> 00:04:58.480
So, historically speaking, just for our for our audience, what have the common treatments for cancer been?
00:04:58.720 --> 00:05:01.519
Is it mostly like surgical removal and radiation?
00:05:01.600 --> 00:05:03.839
And that's sort of the what it's generally been.
00:05:04.079 --> 00:05:04.319
Yeah.
00:05:04.480 --> 00:05:09.040
So there are three major pillars that has helped an enormous amount of people.
00:05:09.199 --> 00:05:15.279
One is surgery, where you can actually debulk the tumor or sometimes even entirely remove the tumor.
00:05:15.519 --> 00:05:19.920
And then the second is radiation therapy, and the third is chemotherapy.
00:05:20.160 --> 00:05:24.160
So surgery usually removes the bulk of the tumor.
00:05:24.399 --> 00:05:33.519
And radiation therapy, it actually causes DNA damage specifically inside the cells by causing radiation.
00:05:33.680 --> 00:05:36.800
And so the cancer cells they don't have a very protective mechanism.
00:05:36.879 --> 00:05:40.160
So with the damaged DNA, they actually tend to die.
00:05:40.319 --> 00:05:46.160
Normal cells, they have intact mechanisms, so even if they are a little bit damaged, they can recuperate from that.
00:05:46.399 --> 00:05:51.439
And then chemotherapy often targets very rapidly dividing cells.
00:05:51.680 --> 00:06:09.600
So um they when the the downside of that is there are some normally rapidly dividing cells as well, so you get a lot of side effects, but um still these three has been the gold standard therapy for years and years.
00:06:10.000 --> 00:06:18.879
And recently, um immunotherapy and targeted therapies are have become like two additional major pillars.
00:06:19.040 --> 00:06:32.639
So in targeted therapy, we actually find what is the molecular change that is actually present inside a cancer cell, and then can we specifically block the changes brought about by those mutations?
00:06:32.879 --> 00:06:39.839
And so you try to selectively kill the cancer cells, and majority of the normal cells can still survive.
00:06:39.920 --> 00:06:43.519
And that's the goal in immunotheraped therapy.
00:06:43.680 --> 00:06:51.600
In immunotherapy, we actually help our own body's immune mechanism to recognize the cancer cells and try to kill them.
00:06:51.759 --> 00:07:00.000
So immunotherapy is also doing well, but unfortunately, it doesn't work very well for a number of tumors like pancreatic cancer, for example.
00:07:00.240 --> 00:07:03.120
Immunotherapy has not has not been very successful.
00:07:03.360 --> 00:07:15.120
So, what people have been trying to do is to convert what we call as a cold tumor immunologically, convert them into a hot tumor, and so it can actually respond to immunotherapy.
00:07:15.199 --> 00:07:20.959
So these are some of the exciting areas of uh therapies that have been improving
over the last several years.
00:07:21.199 --> 00:07:28.240
And now you mentioned with targeted therapy, the idea is it focuses on the cancer cells and leaves all the other cells alone.
00:07:28.480 --> 00:07:39.360
And that's one of the struggles with some of those kind of classic cancer treatments like radiation and chemotherapy, is that it does do some damage to non-cancer cells as well as cancer cells, correct?
00:07:39.519 --> 00:07:39.920
That's right.
00:07:40.079 --> 00:07:40.639
That's right.
00:07:40.959 --> 00:07:50.160
So, you know, in with the current trend and our knowledge that we've got, I don't think there is one single magic bullet for cancer treatment.
00:07:50.319 --> 00:08:05.759
So even though there might be very efficient targeted therapy or immunotherapies coming together, they often will be used in the clinic depending on the context, in combination with radiation or surgery.
00:08:05.920 --> 00:08:09.360
And that's really our best bet to move forward.
00:08:09.759 --> 00:08:10.000
Right.
00:08:10.079 --> 00:08:22.160
So there's there's no the what's the classic term, there's no one size fits all in terms of dealing with cancer, but it is these little using a little bit of this and a little bit of that, finding the right kind of mixture for for each person.
00:08:22.399 --> 00:08:22.800
That's right.
00:08:22.959 --> 00:08:25.519
That's the current standard of care that we are actually moving.
00:08:25.920 --> 00:08:34.240
Um but that being said, um the real goal for cancer research is actually go towards personalized medicine.
00:08:34.399 --> 00:08:41.279
Because if you think about it, uh, you know, the glasses that we wear, my glass won't fit you and yours won't fit mine.
00:08:41.440 --> 00:08:43.360
And that's actually very personalized to me.
00:08:43.440 --> 00:08:44.720
It's a personalized prescription.
00:08:44.960 --> 00:08:50.960
So can we actually make um you know cancer therapy in a more personalized fashion?
00:08:51.120 --> 00:08:57.679
And that is one of the major directions of most of the cancer research that is going on in today's world.
00:08:58.000 --> 00:09:00.879
So let's jump into some of this cancer research then.
00:09:01.039 --> 00:09:13.200
We we talked about how it has evolved, but for your lab, uh, you when we talked before a little bit of behind the scenes, we talked to all of our researchers before we sit down for these great conversations.
00:09:13.279 --> 00:09:20.399
And you mentioned a term to me that I wanted to address here today, and it was called first in class treatment development.
00:09:20.720 --> 00:09:27.200
Can you tell me what that means and how it fits into what your lab is looking at for treating cancer?
00:09:27.519 --> 00:09:29.919
Yeah, you know, uh that's a great question.
00:09:30.080 --> 00:09:37.200
So, you know, I I often, you know, whenever I give talk or explain it to students, I use uh a number of different analogies.
00:09:37.440 --> 00:09:40.559
So our lab is interested in first in class.
00:09:40.639 --> 00:09:42.240
So what is what does that even mean?
00:09:42.480 --> 00:10:00.720
So if you traditionally look at um cancer therapy, we if we find a molecule that works well for cancer treatment, then what we try to do is we make that molecule even more potent, more selective, and and very limited side effects.
00:10:00.879 --> 00:10:08.240
And that's really improving that molecule so that it can actually reach and help that patient in a better way.
00:10:08.399 --> 00:10:13.679
So these are called next in class uh drug development direction.
00:10:14.000 --> 00:10:15.600
And it's an important area.
00:10:15.759 --> 00:10:23.519
There have been several improvements in, for example, PARP inhibitors for some of the breast cancer treatment and even in pancreatic cancer treatment.
00:10:23.600 --> 00:10:26.000
Um, and these are important agents.
00:10:26.399 --> 00:10:31.039
But first in class drugs asks a much more difficult question.
00:10:31.200 --> 00:10:37.039
Um, can we find ways that we have never actually discovered before?
00:10:37.200 --> 00:10:39.759
Can we exploit cancer in a completely new way?
00:10:40.000 --> 00:10:43.279
And that is the space that is actually very interesting to my lab.
00:10:43.440 --> 00:10:48.480
So in my lab, we often focus on what we call as the first-in-class drug discovery molecules.
00:10:48.720 --> 00:11:05.600
So the way we actually do that in in simple sentence as an analogy is that let's say I want to go from spot A to spot B, and and then you know, there if you ask the Google map, it can give you multiple different ways.
00:11:05.840 --> 00:11:14.879
And and and those roads are fantastic, but we are using the same roads, maybe with sophisticated cars, right?
00:11:15.279 --> 00:11:21.519
Cars with that are incredibly fast or with powerful navigation systems and even self-driving cars.
00:11:21.759 --> 00:11:28.480
And we've been making those kind of better cars, but can we actually figure out a better way to reach our target?
00:11:28.639 --> 00:11:32.399
And that's really the mapping that is associated with that.
00:11:32.639 --> 00:11:40.639
So in our lab, we figure out new pathways and how we can actually target some of the cancer cells uniquely.
00:11:40.720 --> 00:11:43.919
And what is the vulnerabilities associated with this cancer cells?
00:11:44.080 --> 00:11:46.320
And is there a way that we can block that?
00:11:46.480 --> 00:11:50.159
And if we block that, how do we do that genetically?
00:11:50.240 --> 00:11:54.480
And can we actually develop a molecule that can actually recapture that as well?
00:11:54.720 --> 00:11:58.159
So those are the kind of research that we actually do.
00:11:58.399 --> 00:12:13.840
Um, recently we our group published a paper where we identified a molecule that if we if you inhibit this particular gene, now the chromosome ends of the cancer cells alone, they start fraying apart.
00:12:14.080 --> 00:12:30.559
And and so we're
now using AI-based technologies to virtually screen millions of small molecules and find what is the potential molecule that can actually go and bind this target inside the cell.
00:12:30.720 --> 00:12:33.759
And can we inhibit the protein that we found?
00:12:33.919 --> 00:12:39.440
And and so once we optimize this small molecule, this can eventually become a drug.
00:12:39.600 --> 00:12:44.879
So this is one of the first in-class kind of therapy that we are actually figuring out.
00:12:45.120 --> 00:12:51.840
Normal cells with this kind of chromosome fraying, it doesn't really happen because of the mechanism that we show in the paper.
00:12:52.000 --> 00:12:52.320
Right.
00:12:52.559 --> 00:13:00.960
Um, but really we have figured out a mechanism where we can selectively kill only the cancer cells, but not the non-malignant cell population.
00:13:01.360 --> 00:13:09.440
And so then we go in for a drug discovery platform where we find these molecules and bring it back into the clinics.
00:13:09.679 --> 00:13:21.120
And now when you're talking about pathways, new pathways for attacking cancer cells and and new like developing molecules to target certain things, this is on this is like a genomics level thing.
00:13:21.279 --> 00:13:29.679
We are looking at the genome of cancer cells and how we can target that versus targeting healthy cells.
00:13:30.000 --> 00:13:31.200
That's absolutely correct.
00:13:31.440 --> 00:13:37.120
So um let me step back a little bit and explain this.
00:13:37.360 --> 00:13:46.639
So the the human cells, if you actually take any of those cells, we have about 20,000 different genes in there, at least from our understanding so far.
00:13:46.960 --> 00:13:47.360
Right.
00:13:47.600 --> 00:13:54.720
And each of these genes can do multiple different functions and some overlapping functions too.
00:13:55.039 --> 00:14:12.559
And so one of the key roles is figuring out how there is a crosstalk within this genetic relationships between all of these different 20,000 genes and figuring out what should I block so that I can actually completely block the cancer cells.
00:14:12.799 --> 00:14:17.600
And if you think about it, uh let's say we have uh the Toronto subway system.
00:14:18.080 --> 00:14:32.159
If there is a block in Kipling Station, Kipling Station is at the far end of the one of the track, you know, the rest of the network can still be functioning relatively well.
00:14:32.320 --> 00:14:32.480
Right.
00:14:32.639 --> 00:14:37.200
It's only the last subway station we can deal with that.
00:14:37.440 --> 00:14:47.919
But if Blue Run Young subway station gets affected, which is actually the central hub of the Toronto, yeah, then the whole system collapses because none of the trains can actually move back and forth.
00:14:48.080 --> 00:14:51.279
Everything, the whole city is probably would come to a stall.
00:14:51.600 --> 00:14:57.360
And and so can we actually figure out those hubs within those cancer cell networks?
00:14:57.519 --> 00:15:00.639
And how do we do that in a very unbiased way?
00:15:00.799 --> 00:15:03.279
And this is actually the type of research.
00:15:03.440 --> 00:15:15.759
So, what we do in the lab, we have um a gene editing system which uh received the Nobel Prize recently, um, and and it's called the CRISPR-based gene editing.
00:15:15.919 --> 00:15:31.360
And so we do a CRISPR-based genome editing to knock out every single gene within these cancer cells and figure out what gene I should turn off or knock out so that it kills only the cancer cells, but not the normal cells.
00:15:31.519 --> 00:15:42.240
So I actually turn off every single 20,000 gene, both in the normal cells and in the cancer cells, and simply figure out by uh large-scale genomic unbiased effort.
00:15:42.399 --> 00:15:48.879
And so these unbiased efforts usually give like completely unexpected mechanisms that we never knew about.
00:15:49.120 --> 00:15:49.519
Right.
00:15:49.759 --> 00:15:55.519
And oftentimes we find ourselves in, oh geez, I don't know anything about these pathways, right?
00:15:55.840 --> 00:16:14.080
And so sometimes we actually reach out to the experts and sometimes we just read all about it and what is in the literature and try to come up with different experiments and see why it kills only these malignant cells and not the non-malignant cells, and understand the mechanisms around it.
00:16:14.320 --> 00:16:14.480
Right.
00:16:14.559 --> 00:16:29.120
Because it's one thing to figure out like I'm I'm imagining this as you have a uh you walk into a room and you have a bank of 20,000 light switches, and you need to figure out which light switch is gonna kill the lights in this room, but not also you know, turn off the internet or something like that with the router plugged in.
00:16:29.440 --> 00:16:30.320
You're absolutely correct.
00:16:30.399 --> 00:16:31.200
You're point on.
00:16:31.440 --> 00:16:32.159
So yeah.
00:16:32.399 --> 00:16:43.840
So when you're but when you do this, when you're knocking out all these genes and doing that testing, it's one thing to figure out which one is maybe gonna take out a cancer cell, but then you have to kind of figure out why.
00:16:44.240 --> 00:16:44.639
Yes.
00:16:44.879 --> 00:16:57.440
So that's the important part of uh um our our work, because it's not just find something that kills the cell, but it actually we need to understand why it kills the cell.
00:16:57.679 --> 00:17:03.919
And because understanding that will help us to navigate any resistant mechanisms.
00:17:04.160 --> 00:17:08.559
So, oh, if I block this, that thing can pop up and compensate.
00:17:08.720 --> 00:17:10.960
So is that really a good target?
00:17:11.200 --> 00:17:23.599
And and so those kind of understanding around those pathways is really important so that we also do not give the opportunity for the cancer cells to adapt and and come back with resistance.
00:17:23.839 --> 00:17:29.599
And and so often people do this in in
different cancer cells.
00:17:29.839 --> 00:17:43.839
But what we try to do is in the context of the factor that I said about tumor heterogeneity, where almost every single cell is different, we look for what are the most common denominators for all of the cancer cells.
00:17:44.000 --> 00:17:44.319
Right.
00:17:44.559 --> 00:17:48.079
And in that context, what should we actually target?
00:17:48.319 --> 00:17:55.039
So this way, your non-malignant cells can also maybe sometimes depend on those pathways and so on, right?
00:17:55.119 --> 00:17:55.279
Right.
00:17:55.440 --> 00:18:00.000
Because let's say, for example, I block um the energy-producing mechanism.
00:18:00.160 --> 00:18:03.200
If I do that, normal cells also need the energy, right?
00:18:03.359 --> 00:18:03.519
Right.
00:18:03.759 --> 00:18:09.839
So, how can I block selectively only the cancer cells if I just block the metabolic pathway, right?
00:18:10.079 --> 00:18:16.400
So, is there a specific need for the cancer cells in producing that energy or depending on that energy?
00:18:16.559 --> 00:18:18.640
And how can we selectively block that?
00:18:18.799 --> 00:18:19.039
Right.
00:18:19.279 --> 00:18:24.319
And so one of the ways that we looked at it is the enzyme telomerase.
00:18:24.480 --> 00:18:30.319
It's like fueling the cancer cells, and and and the beautiful thing is that normal cells don't have this enzyme.
00:18:30.480 --> 00:18:30.799
Okay.
00:18:30.960 --> 00:18:39.839
And so people have been trying to inhibit this enzyme for over two decades, but this has not been very powerful yet.
00:18:40.160 --> 00:18:47.680
And the reason for that is it takes quite a bit of time for the telomerase loss of function to actually cause cell death.
00:18:47.920 --> 00:18:48.160
Okay.
00:18:48.319 --> 00:18:53.119
And so within that time, the cells can actually adapt, rewire, and come back again.
00:18:53.359 --> 00:18:53.599
Okay.
00:18:53.759 --> 00:19:00.160
So even with some of these targeted treatments, you're still seeing the cells are figuring out ways around them that you maybe couldn't have.
00:19:00.960 --> 00:19:01.839
Absolutely, absolutely.
00:19:02.000 --> 00:19:03.599
So there are two things that happen usually.
00:19:03.759 --> 00:19:14.079
One is there are subtonal populations that are not dependent on that at all, or there are a subpopulation of cells that can actually adapt and rewire during the treatment.
00:19:14.240 --> 00:19:14.400
Right.
00:19:14.559 --> 00:19:16.319
They developed during the treatment, even.
00:19:16.400 --> 00:19:16.799
Yeah, okay.
00:19:17.200 --> 00:19:18.400
Resistant mechanisms.
00:19:18.640 --> 00:19:24.319
For uh example, you know, in prostate cancer, we have uh androgen deprivation therapy.
00:19:24.400 --> 00:19:30.079
And this is like the most important standard of care, really helped an enormous amount of patients.
00:19:30.400 --> 00:19:40.799
And one of the drug that actually used in therapy, enzalutamide, can actually cause a treatment-induced resistant mechanism.
00:19:41.039 --> 00:19:47.599
It's called a transdifferentiation of those cancer cells, becoming like a neuroendocrinal cells.
00:19:47.759 --> 00:19:55.279
And so this neuroendocrinal cells are much more aggressive, and these are actually treatment-induced resistant mechanisms.
00:19:55.359 --> 00:19:59.680
So they adapt and then regrow into a more aggressive tumor type.
00:19:59.839 --> 00:20:01.839
So, how do we actually stop those pathways?
00:20:02.000 --> 00:20:03.680
What is the molecular mechanisms?
00:20:03.839 --> 00:20:08.720
What makes those cells to make that decision to move into that aggressive pathway?
00:20:08.880 --> 00:20:11.680
If we can we actually figure those things out and block them.
00:20:11.839 --> 00:20:15.200
So, this is one of the angles that actually our research focus.
00:20:15.359 --> 00:20:22.720
So, understanding the mechanism is one of the fundamental requirements to actually come up with like very strong therapeutic strategies.
00:20:23.039 --> 00:20:23.200
Right.
00:20:23.279 --> 00:20:33.119
So it's not just it's not only looking for new pathways to take out cancer, but also, like you said, like supplementing some of these very effective treatments that already exist.
00:20:33.279 --> 00:20:41.200
Like this is a, you mentioned this is an effective drug for prostate cancer, but there is this one sort of wild, unfortunate, I assume rare side effect.
00:20:41.519 --> 00:20:42.400
It's a rare side effect.
00:20:42.480 --> 00:20:42.640
Yes.
00:20:42.880 --> 00:20:48.400
It's about like uh roughly around uh 15 to 20 percent of the cases, right?
00:20:48.640 --> 00:20:51.519
They develop into neuroendoctrinal prostate cancer.
00:20:51.920 --> 00:21:03.039
But then potentially, though, if you could figure out why it does that's right with genomics, then you could say we'll give this drug that we know works, and also we'll add this to make sure they don't turn into something else.
00:21:03.359 --> 00:21:03.839
That's correct.
00:21:03.920 --> 00:21:04.559
That's correct.
00:21:04.799 --> 00:21:09.599
And you know, at the same time, figuring out mechanisms can sometimes take years.
00:21:09.839 --> 00:21:10.079
Right.
00:21:10.319 --> 00:21:12.640
So is there a way to fast track things?
00:21:12.799 --> 00:21:20.079
And so our lab also dash pharmac um pharmacotyping or what we call as drug repurposing.
00:21:20.400 --> 00:21:35.279
So um if you think about Everlimus, which is one of the drugs that has been used as a standard of care for several years, um was originally uh a transplant-associated drug, like organ transplants.
00:21:35.359 --> 00:21:35.440
Right.
00:21:35.680 --> 00:21:38.880
So you wanted to suppress the immune system for acceptance.
00:21:39.359 --> 00:21:59.759
And this drug is now become the mainstate drug for some of the malignancies in so and so are there drugs that are already FDA approved, and we know the the toxicity associated, in what conditions we can
actually use, what are the side effects of those drugs?
00:22:00.160 --> 00:22:01.920
Drugs, all of these properties.
00:22:02.160 --> 00:22:14.640
And so what we do in our lab is can we actually take some of these drugs and actually directly hit them on cancer cells and figure out if any of those drugs can also be repurposed for treatment?
00:22:14.880 --> 00:22:21.279
And so our lab does not only genetic screens, but we also do pharmacotyping screens.
00:22:21.519 --> 00:22:32.960
And lately, um, one of the very interesting directions that we've been heading towards is uh an organoid-based therapy.
00:22:33.200 --> 00:22:43.119
And and so traditionally, what we usually do is we discover the biology using different cell models and so on that are usually engineered in our lab.
00:22:43.599 --> 00:22:49.759
And and then we figure out what um uh target that we can actually inhibit.
00:22:49.920 --> 00:22:50.319
Right.
00:22:50.559 --> 00:23:02.319
But because these are actually in all the discovery happens in the engineered model that are done within the lab, we then take these targets and test them in human relevant models.
00:23:02.640 --> 00:23:09.279
But to do that, what we initially started doing was making patient-derived models.
00:23:09.359 --> 00:23:21.039
So we take a small tissue from the patient from the surgery, and then we bring it to our lab, um, all approved by the research ethics board, and then with the patient's consent.
00:23:21.200 --> 00:23:29.359
And and then once it arrives in our lab, we actually try to make mini microtumors or avatars of those tumors.
00:23:29.599 --> 00:23:36.400
So when you say take a sample from a patient, you're talking about like taking a sample of the of the tumor that they have, of the cancer that's afflicting them.
00:23:36.640 --> 00:23:37.519
That's right, that's right.
00:23:37.680 --> 00:23:41.119
So these are actually so we now work with uh Dr.
00:23:41.200 --> 00:23:46.400
Mike Moser, who who actually gives us a lot of pancreatic samples.
00:23:46.640 --> 00:23:49.519
And we, my my lab and and my collaborator, Dr.
00:23:49.599 --> 00:23:52.079
Andrew Frewell's lab, we work together a lot.
00:23:52.160 --> 00:24:01.839
So with Laura Hopkins, we get ovarian cancer samples, and we also get uh some pediatric tissues for from patient samples, and we get them into our lab.
00:24:01.920 --> 00:24:09.759
So we've set up a WhatsApp group within uh uh 20 to 30 minutes of the surgical uh procedure.
00:24:10.000 --> 00:24:14.720
These samples, if the patient consents, are brought to our lab right away.
00:24:14.960 --> 00:24:27.359
And and then we try to use these models, we generate these, use these tissues to generate living tumor-like models that closely matches that of the original tumor.
00:24:27.519 --> 00:24:27.759
Right.
00:24:28.000 --> 00:24:38.160
And so we sequence the DNA, make sure that it is actually very similar to that of the original tumor, and then we do our discovery biology within those organoids.
00:24:38.559 --> 00:24:46.000
So this is where when we were talking at the beginning about personalizing and customizing cancer treatment, this is sort of that next level.
00:24:46.160 --> 00:24:55.839
We have the genomic tools, and now this is instead of looking for that one size fits all, this is one of those avenues into spec specifics for each individual patient.
00:24:56.240 --> 00:24:57.279
They're absolutely correct.
00:24:57.519 --> 00:25:08.960
So, you know, rather than asking, what can I, what kind of treatment can I actually bring to a prostate cancer patient or um a pancreatic cancer, right?
00:25:09.279 --> 00:25:15.519
Instead, what can I bring as a treatment to this individual patient, to this specific patient?
00:25:15.680 --> 00:25:21.519
And and and so it's still in the research level, it hasn't gone yet into the clinic.
00:25:21.599 --> 00:25:22.240
So I want to be able to do that.
00:25:22.400 --> 00:25:24.079
But this is the future of what we're trying to do.
00:25:24.400 --> 00:25:24.880
That's right.
00:25:25.039 --> 00:25:26.880
So think about it this way.
00:25:27.119 --> 00:25:41.279
Um, you know, when when uh a patient is first initially diagnosed that he or she might have a cancer, there is a window where the whole treatment team works together.
00:25:41.440 --> 00:26:04.079
The pathologist looks at these tumors under the microscope, figure out what is the nature of those tumor cells, and then if part of those tissue is actually sent to DNA sequencing to figure out what mutations are associated, and then the same patient also goes in for imaging-based studies to see where else the tumor is present and how big are those tumors by imaging.
00:26:04.240 --> 00:26:17.359
Now, with all of these information, the clinician now gets this and and looks at what kind of treatment they can actually come, you know, to come up with uh to treat this patient.
00:26:17.599 --> 00:26:53.839
Now, what we are trying to accomplish is within this time span, within this window of time where all of these diagnostic approaches are being done, can we also get a small tissue or a tumor sample from the patient with the patient's consent, and then make these organoid-like structures and grow them live in Peterdicious within our lab, make sure that the fidelity of these organoids are absolutely very close to that of the original tumor, and then hit them with like 1,800 different FDA-approved drugs.
00:26:54.000 --> 00:26:55.279
And that's what we do.
00:26:55.519 --> 00:27:08.559
Then we can actually go back and tell to the clinician within that window of span hey, there might be also a potential drug that might even respond to this particular cancer.
00:27:08.799 --> 00:27:15.279
And so now the clinician has all the information, including what are the priorities of drug that he can actually give to those patients.
00:27:15.440 --> 00:27:34.960
And this would be a phenomenal way to personalize what treatment can actually go to that
individual person, because it's no longer dependent on okay, the overall statistics say, like, you know, 35% of these patients will respond to given therapy, but instead saying, What will your tumor respond to?
00:27:35.440 --> 00:27:37.519
That would be the goal that we wanted to go after.
00:27:37.759 --> 00:27:38.960
And this comes back to that.
00:27:39.039 --> 00:27:45.039
Um, and I'm making sure I use the right term, that cancer heterogeneity you talked about, when it is everything is a little different.
00:27:45.200 --> 00:27:51.839
So when when doctors are working with patients, when clinicians are working with patients, it is it is percentages.
00:27:51.920 --> 00:27:59.279
It's like this drug helps a majority of the patients with this kind of cancer, but it's not necessarily going that we can't 100% guarantee.
00:27:59.440 --> 00:28:14.000
But with this, in theory, with this new sort of organoid avatar uh study that you're doing, the idea would be is you could go back to the doctors and say, we've tested 1800 drugs on this on this cancer sample.
00:28:14.079 --> 00:28:14.160
Yeah.
00:28:14.319 --> 00:28:18.960
And based on our testing, we know that drug A, B, and C have shown the best results.
00:28:19.200 --> 00:28:19.599
That's right.
00:28:19.839 --> 00:28:21.680
So let me put it this way.
00:28:21.920 --> 00:28:29.119
Um currently, for you know, it's it's funny because my undergraduate degree was in clinical laboratory science.
00:28:29.279 --> 00:28:30.720
I did this degree in India.
00:28:30.960 --> 00:28:41.839
So the the purpose of this uh uh degree was, you know, we would collect urine samples, blood samples when there is an infection, right?
00:28:42.160 --> 00:28:46.240
And and then the doctor has to prescribe an antibiotic, right?
00:28:46.480 --> 00:28:50.480
Or you go to the doctor's office, they would take a throat swab, right?
00:28:50.640 --> 00:29:12.960
And then all these urine samples or throat swabs and and blood samples, they when they come into the lab, what we usually do, I used to do this as an undergraduate student, and and uh part of my work as a after my undergrad degree as well, is we would take these urine samples and then try to grow them in certain media, like you spread them on media.
00:29:13.119 --> 00:29:20.720
Okay, and then if there is a bacteria that has infected the urine, these bacteria actually can grow as well on that you on the plate.
00:29:21.359 --> 00:29:30.319
Now, I take like a whole bunch of different antibiotics and I test which antibiotic is actually killing those bacteria, right?
00:29:30.880 --> 00:29:34.960
Now it's been used in the clinic for years, right?
00:29:35.200 --> 00:29:38.319
Or like, I don't know, 1950s or so, right?
00:29:38.559 --> 00:29:40.559
We're doing very similar things here.
00:29:40.720 --> 00:30:09.039
Instead of growing the bacteria and figuring out what antibiotic can kill them, here we're now figuring out a way to get the cancer cells and try to grow them in a way in an environment that it closely mimics that of the human body and maintain that genetic fidelity and then hit them with like a hundreds of drugs and figuring out what drug might actually work better.
00:30:09.279 --> 00:30:22.000
Because after all of these uh precision therapy and personalized therapy, we talk about, when it finally comes down to that individual patient, the doctors have to still make a little bit of a guesswork.
00:30:22.160 --> 00:30:27.200
Okay, there are four great drugs that have been working for this particular cancer type.
00:30:27.440 --> 00:30:29.680
Which of those four can I give that patient?
00:30:29.759 --> 00:30:30.079
Right.
00:30:30.559 --> 00:30:33.279
You still have to make a guesswork in there.
00:30:33.519 --> 00:30:39.119
And it's actually a challenging time, especially on aggressive cancers, time is of essence.
00:30:39.200 --> 00:30:43.200
And so you don't want to go in and, you know, let's try this.
00:30:43.279 --> 00:30:45.440
And if it doesn't, we will put this drug.
00:30:45.759 --> 00:30:55.359
But instead, if we can rank order what are the most optional and you know, potential drugs and prioritize those drugs and give that to the clinician, this will be a huge help.
00:30:55.519 --> 00:30:58.240
But again, currently it's all in the research level.
00:30:58.319 --> 00:30:58.559
Yes.
00:30:58.720 --> 00:31:01.279
But that'll be the goal that we wanted to walk towards.
00:31:01.440 --> 00:31:04.400
And this is called as the organoid-based therapy.
00:31:04.559 --> 00:31:10.079
And several institutions have actually, MD Anderson and actually initiated a client trial towards that.
00:31:10.319 --> 00:31:14.880
And multiple institutions have been getting in this direction.
00:31:15.119 --> 00:31:29.440
The the challenge right now is the amount of time that is required to expand those organoid cultures and hit them with all the drugs and figuring out what is the best drug.
00:31:29.599 --> 00:31:39.599
Can we actually do that as quickly as possible so that when the clinician gets the remaining diagnostic information, can we have this information at that same time?
00:31:39.759 --> 00:31:40.000
Right.
00:31:40.240 --> 00:31:44.079
That's really the goal that we wanted to move forward to.
00:31:44.720 --> 00:31:48.480
On, you know, you mentioned like trying like bombarding these samples with all these drugs.
00:31:48.559 --> 00:31:55.279
And my my first thought honestly was well, yes, because you can't just give a patient 1800 drugs and try to figure out which one is best.
00:31:55.359 --> 00:32:01.839
You have to do this in a different setting so you can go and and not poison a patient with thousands, a thousand drugs.
00:32:02.160 --> 00:32:02.640
That's right.
00:32:02.960 --> 00:32:21.200
So the this um this organoid-based therapy of knowing how to grow the cancer cells with high fidelity to matching that of the original tumor, has been a huge challenge.
00:32:21.359 --> 00:32:22.319
How do we
do that?
00:32:22.480 --> 00:32:26.160
And so there's a um a very famous German scientist, Dr.
00:32:26.240 --> 00:32:30.640
Hans Klaver, and he was the first pioneer in this area.
00:32:30.799 --> 00:32:35.680
He figured out some of the ways how we can develop uh these organoid models.
00:32:36.319 --> 00:32:48.319
And so, since his time, like about uh 10 years ago, when he actually published some of his uh major methods, things have slowly starting to take place.
00:32:48.400 --> 00:32:57.279
And now we are moving towards this faster, less expensive way, actually, relatively, because the previous ways were like you'd have to test them in animal models.
00:32:57.440 --> 00:32:57.759
Right.
00:32:58.000 --> 00:33:02.480
And we are absolutely great in curing all of the mice's tumors.
00:33:02.559 --> 00:33:05.920
Uh, and unfortunately, not with the human tumors, right?
00:33:06.160 --> 00:33:11.519
And so that's because we need to have relevant human models to test them.
00:33:11.680 --> 00:33:13.519
And so this approach of Dr.
00:33:13.599 --> 00:33:19.119
Hans's clever, Hans Clever has actually taken a paradigm shift in the field.
00:33:19.279 --> 00:33:22.000
And that's where we are now heading towards.
00:33:22.319 --> 00:33:23.440
Absolutely.
00:33:23.759 --> 00:33:32.640
So we've talked about genomic tools and we've talked about the different kinds of drug therapies and how they're working in tandem.
00:33:32.720 --> 00:33:41.759
And that's really it is some of this sort of customized, personalized treatment, is work them working together to figure out the best ways to deal with different cancers.
00:33:42.000 --> 00:33:48.880
So as we we look ahead, you talked about this organoid treatment is is a research idea right now.
00:33:48.960 --> 00:33:52.400
It has not been taken to to clinical trial or anything like that yet.
00:33:52.880 --> 00:34:01.759
What does the future of cancer treatment look like, in your opinion, as we we look ahead to some of this research and some of these other genomic tools we have?
00:34:01.920 --> 00:34:05.519
What what do you see as the next the next steps in cancer research?
00:34:05.759 --> 00:34:26.719
You know, I I I have maybe it's a bold dream, but um for me the the complete um the best way if you can think of is the moment a patient walks into our clinic, we basically, okay, these are your mutations, right?
00:34:27.280 --> 00:34:31.920
These are your cancer dependencies or vulnerabilities, right?
00:34:32.559 --> 00:34:36.960
And then put that in a database, right?
00:34:37.199 --> 00:34:39.760
And then it tells you exactly, okay, here it is.
00:34:39.840 --> 00:34:41.519
These are the drugs you should actually give.
00:34:41.679 --> 00:34:57.440
Because with the development of AI and the knowledge that we have over the last few years and that we will be developing, you don't really have to, you know, um uh have to go in and and spend a lot of time.
00:34:57.599 --> 00:35:03.840
We wanted to make cancer at least to an extent of like how we deal with diabetes now, right?
00:35:04.000 --> 00:35:14.079
Because there's several people living with diabetes, but it's not life-threatening because you can there are good medications available and you can still live with it, right?
00:35:14.239 --> 00:35:14.480
Right.
00:35:14.639 --> 00:35:22.719
I don't I don't know if we will have a cancer-free world, but we would be able to have in a way that we can manage cancer.
00:35:22.880 --> 00:35:23.119
Okay.
00:35:23.280 --> 00:35:39.199
And how do we achieve that is basically looking at the the complete complexity of the genetic interactions, and because I'm a basic scientist and I I think from that side is to figure out the genetic crosstalk of all the genes within the cells.
00:35:39.360 --> 00:35:43.599
Whatever cell type we have, we know how these genes actually crosstalk.
00:35:43.840 --> 00:35:46.079
And if I push this button, this will pop up.
00:35:46.159 --> 00:35:47.920
If I push this button, that'll pop up.
00:35:48.079 --> 00:35:53.199
And I know all of these, which ones will like will come up.
00:35:53.360 --> 00:36:00.320
And once I know this sort of pattern, then can I actually predict which will be the best drug to just keep them all shut?
00:36:00.559 --> 00:36:03.039
And that'll be the direction that we wanted to head towards.
00:36:03.280 --> 00:36:26.079
So mapping the complete genetic relationships of all genes, having the structure of most potential targets that we can have, and and have small molecule inhibitors that are there, or even biologics like antibody drugs and so on that can be used immediately to generate and and give get back to the patient.
00:36:26.320 --> 00:36:32.639
So those are the complete information that we need to have completely locked in.
00:36:32.719 --> 00:36:37.760
And once we have that information, we probably can manage cancer in a more efficient way.
00:36:37.920 --> 00:36:40.719
And that would be really the future of cancer research.
00:36:40.880 --> 00:36:43.679
The doctor says, okay, here's your genomic mutations.
00:36:43.840 --> 00:36:46.079
All right, let me punch everything in my computer.
00:36:46.239 --> 00:36:49.519
Ah, these are the drugs that'll definitely going to work for you, right?
00:36:49.679 --> 00:36:58.400
We need to have that level of confidence, and I don't think we are there anywhere near yet, but that would be the phenomenal direction that we wanted to head towards, I think.
00:36:58.639 --> 00:37:14.400
So not only is it the development of new drugs and better drugs, and finding, as you kind of said, those new roads and better roads, but it is setting ourselves up so that we can be fast and efficient and making these decisions quickly and confidently.
00:37:14.639 --> 00:37:15.199
Absolutely.
00:37:15.840 --> 00:37:21.119
That is the fear of of cancer should go away.
00:37:21.440 --> 00:37:26.960
It's like I have diabetes, but it's not, it's okay.
00:37:27.119 --> 00:37:27.920
I can
live with it.
00:37:28.079 --> 00:37:29.440
There are treatments out there.
00:37:29.679 --> 00:37:35.199
If we can reach this stage, I think we've had major success in the world, right?
00:37:35.280 --> 00:37:38.719
Like, so that'll be the direction I think that we need to head towards.
00:37:38.960 --> 00:37:44.239
So what is individual patient will benefit from?
00:37:44.320 --> 00:37:45.760
And that's the direction.
00:37:45.840 --> 00:37:52.639
It's not about the whole, okay, 50% of the people are responding to this, so I'm gonna ignore the rest of the 50 people.
00:37:52.719 --> 00:37:57.519
And we are hoping that for because for that individual patient, it's still a flip of a coin, right?
00:37:57.920 --> 00:38:00.880
Maybe you fall into that 50%, maybe you don't.
00:38:01.039 --> 00:38:04.000
And so it's so sad.
00:38:04.239 --> 00:38:07.039
Oh, we have a therapy that'll work for 50%, right?
00:38:07.280 --> 00:38:19.760
Instead, if we can actually go in and have personalized therapy, truly personalized, like our glasses, I think we we will be in a very much better state to deal with this.
00:38:20.159 --> 00:38:21.280
Absolutely.
00:38:21.519 --> 00:38:34.960
You know, when we started off, I kind of commented that we were going to get really detailed down from the idea of what is cancer and those kind of old classic treatment, I say old, the kind of classically accepted treatments that have been very effective, and down to some of the specific.
00:38:35.280 --> 00:38:41.920
Like I if you had asked me before we started, I never could have even imagined getting to there with some of this work that you're doing.
00:38:42.079 --> 00:38:51.599
So, Franco, I just wanted to say thank you again so much for being on the episode with us here today and sharing some of these incredible insights and this incredible research that you're doing here at the university.
00:38:51.840 --> 00:38:53.599
Thank you very much for having me, Matt.
00:38:53.679 --> 00:38:57.760
It's really a privilege, and we're happy to share of the work that we are doing in our lab.
00:38:59.280 --> 00:39:03.280
This has been another episode of the Use Ask Signature Series podcast.
00:39:03.440 --> 00:39:07.760
Thank you so much for listening and for watching, and we hope you tune in next time.
00:39:10.320 --> 00:39:16.719
The USASK Signature Series Podcast is produced by USASK's Office of the Vice President Research.
00:39:16.960 --> 00:39:19.599
Our host and editor is Matt Olson.
00:39:20.079 --> 00:39:23.360
Producers are Matt Olson and Leslie Ann Slosher.
00:39:23.760 --> 00:39:28.800
Technical and studio support is provided by USASK's Media Productions team.
00:39:29.039 --> 00:39:34.639
Graphic design and marketing is provided by USASK's research profile and impact team.
00:39:34.800 --> 00:39:37.360
Our original music is by Silas Friesen.
00:39:37.920 --> 00:39:42.079
This podcast is produced on Treaty 6 territory and the homeland of the Metis.
00:39:42.239 --> 00:39:48.880
We pay our respects to the First Nations and Metis ancestors of this place and reaffirm our relationship with one another.